Losartan: lessons learned from the RENAAL study

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2006-03-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.7.5.623PMID 16553578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

  2007cited by this paper
• Losartan and end‐organ protection—lessons from the renaal study

  2005cited by this paper
• Projecting the number of patients with end-stage renal disease in the United States to the year 2015.

  2005cited by this paper
• Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.

  2005cited by this paper
• Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause?

  2005cited by this paper
• Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.

  2005cited by this paper
• Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

  2005cited by this paper
• The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease.

  2005cited by this paper
• Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

  2005cited by this paper
• Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.

  2004cited by this paper
• Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.

  2004influential reference
• Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

  2004cited by this paper
• Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.

  2004cited by this paper
• Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy

  2004cited by this paper
• Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.

  2004cited by this paper
• Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results: A post hoc analysis of the RENAAL trial results

  2004cited by this paper
• The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

  2003influential reference
• European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension

  2003cited by this paper
• Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

  2003cited by this paper
• Analysis of metabolic parameters as predictors of risk in the RENAAL study.

  2003influential reference
• Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.

  2003cited by this paper
• Dialysis delayed is death prevented: a clinical perspective on the RENAAL study.

  2003influential reference
• Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study.

  2003cited by this paper
• Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.

  2002cited by this paper
• Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.

  2002cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001influential reference
• Forecast of the number of patients with end-stage renal disease in the United States to the year 2010.

  2001cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Proteinuria and plasma compositional changes contribute to defective lipoprotein catabolism in the nephrotic syndrome by separate mechanisms.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

  2001cited by this paper
• [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension].

  2000cited by this paper
• The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

  2000cited by this paper
• Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

  2000cited by this paper
• THE EFFECT OF NISOLDIPINE AS COMPARED WITH ENALAPRIL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES AND HYPERTENSION

  2000influential reference
• SPECIAL REPORT Preserving Renal Function in Adults With Hypertension and Diabetes: A Consensus Approach

  2000cited by this paper
• Guidelines for the management of hypertension.

  2000cited by this paper
• Angiotensin II: a pivotal factor in the progression of renal diseases.

  1999cited by this paper
• The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.

  1998cited by this paper
• Dialysis therapy.

  1998cited by this paper
• Standards of Medical Care for Patients With Diabetes Mellitus

  1998cited by this paper
• Dialysis therapy.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010

  1997cited by this paper
• Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.

  1996cited by this paper
• Blood Pressure Control, Proteinuria, and the Progression of Renal Disease

  1995cited by this paper
• Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.

  1995cited by this paper
• Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis.

  1994cited by this paper
• Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1994cited by this paper
• Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients

  1993cited by this paper
• Standards of Medical Care for Patients With Diabetes Mellitus

  1991cited by this paper
• Effect of captopril on heavy proteinuria in azotemic diabetics.

  1985cited by this paper

• Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial

  2025cites this paper
• Pathogenesis: Hemodynamic Alterations

  2022cites this paper
• Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient

  2022cites this paper
• Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology

  2020cites this paper
• Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study

  2019cites this paper
• DDDT_A_208327 2769..2776

  2019cites this paper
• Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives.

  2010cites this paper
• Rein et diabète

  2008cites this paper
• Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats.

  2007cites this paper
• CALL FOR PAPERS Sex Differences in Renal and Cardiovascular Function: Physiology and Pathophysiology Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats

  2007cites this paper